AbCellera Biologics Inc.

AbCellera Biologics Inc.

11.12
USD
-0.37
(-3.22%)
-0.48EPS
4.76BMarket Cap
Feb 23Next Earn

Total Valuation

USD

As of September 30, 2026, AbCellera Biologics Inc. carries a market capitalization of 4.76B, placing it among publicly traded companies globally. Its enterprise value stands at 4.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.76B
Enterprise Value4.13B

Important Dates

AbCellera Biologics Inc.'s next confirmed earnings release is scheduled for February 23, 2027.

Earnings Date2/23/2027

Share Statistics

As of September 30, 2026, AbCellera Biologics Inc. has 326.33M shares outstanding.

Shares Outstanding326.33M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 65.97, and the price-to-book ratio stands at 4.48.

PS Ratio65.97
PB Ratio4.48
P/TBV Ratio4.88
P/FCF Ratio-136.27
P/OCF Ratio-290.12

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 60.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.13B versus a market cap of 4.76B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales60.87

Financial Position

As of September 30, 2026, AbCellera Biologics Inc. maintains a current ratio of 12.43, meaning it holds 12.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.60, indicating elevated leverage, while an interest coverage ratio of -4,005.19 demonstrates limited ability to service its debt obligations.

Current Ratio12.43
Quick Ratio11.80
Debt / Equity12.60
Debt / EBITDA-0.80
Interest Coverage-4,005.19

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, AbCellera Biologics Inc. posted a negative return on equity (ROE) of -14.64, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.39, reflecting losses generated across the asset base. The company generates approximately 120,741.99 in revenue per employee across its workforce of 562.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-14.64
Return on Assets (ROA)-10.39
Revenue Per Employee120,741.99
Employee Count562.00

Taxes

USD

Over the twelve months ended September 30, 2026, AbCellera Biologics Inc. recorded an income tax benefit of -22.52M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -170.81M and -148.29M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-22.52M

Stock Price Statistics

USD

As of the close on November 16, 2026, AbCellera Biologics Inc.'s stock has gained approximately 201.36% over the past 52 weeks. The 50-day moving average sits at 12.33, while the 200-day moving average is 7.27.

52-Week Price Change201.36%
50-Day Moving Average12.33
200-Day Moving Average7.27

Income Statement

USD

Over the twelve months ended September 30, 2026, AbCellera Biologics Inc. generated 67.86M in revenue and converted that into -148.29M in net income, yielding earnings per share of -0.48. EBITDA reached -168.22M, while operating income came in at -187.05M.

Revenue67.86M
Operating Income-187.05M
Pretax Income-170.81M
Net Income-148.29M
EBITDA-168.22M
EBIT-202.19M
Earnings Per Share (EPS)-0.48

Balance Sheet

USD

As of September 30, 2026, AbCellera Biologics Inc. holds 764.42M in cash and equivalents against 133.82M in total debt, resulting in a net debt position of -163.80M. Total book value stands at 1.06B, with working capital of 805.69M providing operational flexibility.

Cash & Cash Equivalents764.42M
Total Debt133.82M
Net Debt-163.80M
Equity (Book Value)1.06B
Book Value Per Share3.26
Working Capital805.69M

Cash Flow

USD

AbCellera Biologics Inc. produced -15.43M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -17.42M in capital expenditures, free cash flow totaled -32.85M - equivalent to -0.11 per share.

Operating Cash Flow-15.43M
Capital Expenditures-17.42M
Free Cash Flow-32.85M
FCF Per Share-0.11

Margins

These figures cover the twelve months ended September 30, 2026. The operating margin of -275.65 and net profit margin of -218.54 provide insight into operational efficiency.

Operating Margin-275.65
Pretax Margin-251.72
Profit Margin-218.54
EBITDA Margin-247.90

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -0.73: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.59, meaning AbCellera Biologics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-4.59
FCF Yield-0.73

Scores

As of September 30, 2026, AbCellera Biologics Inc. has an Altman Z-Score of 6.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.66